Skip to main content
SpringerLink
Log in

The Pharmacokinetics of Topotecan and Its Carboxylate Form Following Separate Intravenous Administration to the Dog

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To determine the relationship between topotecan and its ring opened hydrolysis product (SK&F 105992) following intravenous administration of the two agents separately, and to determine the bio-availability of topotecan in female beagle dogs.

Methods. The pharmacokinetics of topotecan and SK&F 105992 were determined following separate administration as 30 minute intravenous infusions in a cross-over design. Topotecan was also administered orally to the same dogs.

Results. When administered intravenously to dogs, SK&F 105992 underwent interconversion to topotecan. Plasma concentrations of both topotecan and SK&F 105992 appeared to decline multi-exponentially following IV infusion of either compound. A 2-compartment model was found to adequately characterize the data.

Conclusions. The clearance of topotecan by other routes proceeded at a faster rate than its interconversion to SK&F 105992, whereas the clearance of SK&F 105992 by other routes was slower than the rate of its interconversion to topotecan. Any SK&F 105992 formed in the GI tract did not appear to be well absorbed following oral administration of topotecan to dogs. The steady-state volume of distribution for topotecan was approximately 8- to 9-fold greater than that for SK&F 105992 in the dog. After intravenous administration of topotecan, the amount of topotecan in the dog was much greater than that of the carboxylate, even though their respective plasma concentrations were similar. The bioavailability of topotecan, calculated from oral topotecan data or from SK&F 105992 data, was approximately 50%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. L. F. Liu. Annu. Rev. Biochem. 58:351-375 (1989).

    PubMed  Google Scholar 

  2. W. J. M. Underberg, R. M. J. Goossen, B. R. Smith, and J. H. Beijnen. J. Pharm. Biomed. Anal. 8:681-683 (1990).

    PubMed  Google Scholar 

  3. L. B. Grochow, E. K. Rowinsky, R. Johnson, S. Ludeman, S. H. Kaufmann, F. L. McCabe, B. R. Smith, L. Hurowitz, A. DeLisa, R. C. Donehower, and D. A. Noe. Drug. Metab. Dispos. 20:706-713 (1992).

    PubMed  Google Scholar 

  4. R. K. Johnson, F. L. McCabe, L. F. Faucette, R. P. Hertzberg, W. D. Kinsbury, J. C. Boehm, M. J. Caranfa, and K. G. Proc. AACR 30:623 (1989).

    Google Scholar 

  5. H. Rosing, E. Doyle, B. E. Davies, and J. H. Beijnen. J. Chromatography B. 668:107-115 (1995).

    Google Scholar 

  6. G. D. Allen. Biopharm. Drug Dispos. 11:477-498 (1990).

    PubMed  Google Scholar 

  7. H. Cheng and W. J. Jusko. In D. Argenio (ed.) Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, Plenum Press, NY, 1991, pp. 13-20.

    Google Scholar 

  8. H. Cheng and W. J. Jusko. Pharm. Res. 7:1003-1010 (1990).

    PubMed  Google Scholar 

  9. H. Cheng, and W. J. Jusko. Biopharm. Drug Dispos. 14:721-766 (1993).

    PubMed  Google Scholar 

  10. I. Walter-Sack, J. X. de Vries, C. Kreiner, A. Ittensohn, G. Stenzhorn, A. Voss, and E. Weber. Clin. Investig. 71:240-246 (1993).

    PubMed  Google Scholar 

  11. M.-L. Chen and A. J. Jackson. Pharm. Res. 8:25-32 (1991).

    PubMed  Google Scholar 

  12. D. O. Scott, D. S. Bindra, S. C. Sutton, and V. J. Stella. Drug Metab. Dispos. 22:438-442 (1994).

    PubMed  Google Scholar 

  13. D. O. Scott, D. S. Bindra, and V. J. Stella. Pharm. Res. 10:1451-1457 (1993).

    PubMed  Google Scholar 

  14. F. M. Muggia, P. J. Creaven, H. H. Hansen, M. H. Cohen, and O. S. Selawry. Cancer Chemother. Rep. 56:515-521 (1972).

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Brian E. Davies

    Present address: Department of Pharmaceutical Analysis and Toxicology, Faculty of Pharmacy, State University of Utrecht, The Netherlands

Authors and Affiliations

  1. Department of Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania

    Brian E. Davies, Elisabeth A. Minthorn & Michael J. Dennis

  2. Department of Pharmacokinetics, Bracco Diagnostics, Princeton, New Jersey

    Hilde Rosing & Jos H. Beijnen

Authors
  1. Brian E. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabeth A. Minthorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael J. Dennis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hilde Rosing
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jos H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Dennis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davies, B.E., Minthorn, E.A., Dennis, M.J. et al. The Pharmacokinetics of Topotecan and Its Carboxylate Form Following Separate Intravenous Administration to the Dog. Pharm Res 14, 1461–1465 (1997). https://doi.org/10.1023/A:1012189225880

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012189225880

Search

Navigation